BIO logo

Bio-Rad Laboratories, Inc. Stock Price

NYSE:BIO Community·US$8.1b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 14 Fair Values set on narratives written by author

BIO Share Price Performance

US$300.63
-32.77 (-9.83%)
31.2% undervalued intrinsic discount
US$437.00
Fair Value
US$300.63
-32.77 (-9.83%)
31.2% undervalued intrinsic discount
US$437.00
Fair Value
Price US$300.63
AnalystHighTarget US$437.00
AnalystConsensusTarget US$310.00
AnalystLowTarget US$265.00

BIO Community Narratives

AnalystHighTarget·
Fair Value US$437 30.7% undervalued intrinsic discount

Global Healthcare Trends Will Fuel ddPCR Expansion Despite Risks

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value US$310 2.3% undervalued intrinsic discount

Molecular Diagnostics Expansion Will Unlock Potential While Cost Challenges Persist

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AnalystLowTarget·
Fair Value US$265 14.3% overvalued intrinsic discount

Increasing Price Controls Will Limit Diagnostics Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent BIO News & Updates

Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause

Aug 07

Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results

Aug 03
Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results

We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Jul 14
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
User avatar

Acquisition And Droplet Digital PCR Will Advance Oncology Diagnostics

Bio-Rad's efforts in digital PCR technology and strategic acquisitions aim to expand applications and bolster revenue through oncology diagnostics and rare mutation detection.

Bio-Rad Laboratories, Inc. Key Details

US$2.6b

Revenue

US$1.2b

Cost of Revenue

US$1.4b

Gross Profit

US$1.0b

Other Expenses

US$319.2m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
11.79
Gross Margin
52.96%
Net Profit Margin
12.50%
Debt/Equity Ratio
16.7%

Bio-Rad Laboratories, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet and good value.

2 Risks
2 Rewards

About BIO

Founded
1952
Employees
7700
CEO
Norman Schwartz
WebsiteView website
www.bio-rad.com

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: 0.3%
  • 3 Months: 8.5%
  • 1 Year: 17.3%
  • Year to Date: 15.0%
The market has stayed flat over the 7 days. As for the longer term, the market has risen 17% in the past 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›